Compare RDNW & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RDNW | VYGR |
|---|---|---|
| Founded | 2013 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 213.0M | 193.5M |
| IPO Year | 2014 | 2015 |
| Metric | RDNW | VYGR |
|---|---|---|
| Price | $5.32 | $1.75 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 11 |
| Target Price | $8.50 | ★ $14.89 |
| AVG Volume (30 Days) | 46.0K | ★ 976.4K |
| Earning Date | 11-10-2026 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 37.84 | N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $1,793,369,000.00 | $10,135,000.00 |
| Revenue This Year | $3.88 | N/A |
| Revenue Next Year | $5.55 | $129.75 |
| P/E Ratio | $89.00 | ★ N/A |
| Revenue Growth | ★ 91.10 | N/A |
| 52 Week Low | $4.08 | $1.68 |
| 52 Week High | $8.55 | $5.19 |
| Indicator | RDNW | VYGR |
|---|---|---|
| Relative Strength Index (RSI) | 50.97 | 37.90 |
| Support Level | $4.64 | N/A |
| Resistance Level | $7.14 | $2.29 |
| Average True Range (ATR) | 0.38 | 0.15 |
| MACD | 0.06 | 0.03 |
| Stochastic Oscillator | 60.33 | 31.71 |
RideNow Group Inc operates solely as a powersports dealership group. Its offerings include new and pre-owned vehicles such as motorcycles, all-terrain vehicles (ATVs), side-by-side vehicles (SXS), and personal watercraft (PWC). It also sells parts, apparel, and accessories, and provides financing, insurance, and aftermarket products, along with repair and maintenance services. The majority of the company's revenue is derived from powersports vehicle sales, and the rest from parts, service and accessories/merchandise, and finance and insurance products.
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.